SHANGHAI, Jan 27 (Reuters) - German drugmaker Boehringer Ingelheim will license an experimental inflammatory bowel disease ...

Boehringer Ingelheim has penned a 1.05 billion euro ($1.26 billion) biobucks deal for Simcere’s preclinical inflammatory bowel disease (IBD) bispecific antibody. | Boehringer Ingelheim has penned a 1.

Novel TL1A/IL23p19 bispecific antibody targets drivers of disease pathogenesis to overcome the efficacy ceiling in inflammatory bowel disease.

Boehringer Ingelheim announced a license and collaboration agreement with Simcere Pharmaceuticals to develop Simcere’s ...

For decades, patients with inflammatory bowel disease have reported a familiar and frustrating pattern: periods of intense stress are often followed by worsening symptoms or full-blown disease flares.

Boehringer Ingelheim has added another drug to its immunology pipeline, licensing an inflammatory bowel disease (IBD) ...

The new molecules selectively reduced inflammatory signaling in human immune cells without affecting other immune pathways. Treatment with the molecules also reduced inflammation in mice with the ...

Real-world analyses suggest link to reduced steroid use, fewer hospital stays, lower morta ...

Single-center study finds durable, steroid-free remission, especially in ulcerative coliti ...

A newly uncovered immune chain reaction in the gut may explain why people with inflammatory bowel disease face a much higher ...

Meta-analysis links caffeine consumption to higher inflammatory bowel disease risk in smokers, those with more education, and ...